Zura Bio Limited (NASDAQ:ZURA) Director Van Amstel Arnout Ploos Purchases 80,000 Shares

Zura Bio Limited (NASDAQ:ZURA) Director Van Amstel Arnout Ploos purchased 80,000 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was bought at an average price of $6.20 per share, for a total transaction of $496,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares in the company, valued at $620,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Zura Bio Price Performance

Shares of Zura Bio stock traded up $0.12 during trading on Thursday, hitting $5.64. 140,164 shares of the company’s stock traded hands, compared to its average volume of 269,153. Zura Bio Limited has a twelve month low of $2.00 and a twelve month high of $13.00. The firm’s fifty day moving average price is $3.71 and its 200 day moving average price is $3.95.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZURA. Oppenheimer raised their price target on shares of Zura Bio from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Piper Sandler began coverage on shares of Zura Bio in a research report on Friday, May 3rd. They issued an “overweight” rating and a $26.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $18.83.

Hedge Funds Weigh In On Zura Bio

Several institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC raised its stake in shares of Zura Bio by 15.4% in the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in shares of Zura Bio in the first quarter worth about $1,157,000. Silverarc Capital Management LLC raised its stake in shares of Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after acquiring an additional 244,040 shares during the last quarter. Eisler Capital US LLC bought a new position in shares of Zura Bio in the third quarter worth about $660,000. Finally, Raymond James & Associates raised its stake in shares of Zura Bio by 14.0% in the third quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares during the last quarter. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.